PhenoPath provides anatomic pathology services for Phase I–III clinical trials. Our team adapts its service delivery to reflect your project design, management and implementation requirements.
PhenoPath is experienced in working with third-party vendors to ensure timely and trackable specimen management, either directly from sponsor sites or another CRO.
PhenoPath understands the need for timely results on entrance criteria testing, and provides rapid turnaround time for biomarker-testing assays. Board-certified pathologists and/or scientists evaluate all assays. Report formats are customizable to reflect either individual case or cumulative case formats.
DIAGNOSIS & INTERPRETATION
RAPID ENTRANCE CRITERIA SCREENING
|SOLID TUMOR PATHOLOGY||HEMATOPATHOLOGY|
|Diagnosis and subtyping (breast, colon, lung, sarcoma, etc.)||Indolent B cell non-Hodgkin lymphoma|
|Undifferentiated malignant neoplasms||Prognostic and predictive markers|
|Carcinomas of unknown primary site||￼Aggressive B cell non-Hodgkin lymphoma|
|Spindle cell tumors/sarcoma subtyping||T cell non-Hodgkin lymphoma|
|Mesothelioma vs. adenocarcinoma||Lymphoblastic leukemia / lymphoma|
|Small, blue, round cell tumors||Hodgkin lymphoma|
|Germ cell neoplasms||Plasma cell neoplasms|
|Skin and mucosal immunofluorescence studies||Acute myeloid leukemias|
|Chronic myeloid neoplasms (MDS & MPN)||Rare hematolymphoid neoplasms|
|Hydatidiform mole evaluation||Benign hematolymphoid proliferations|